BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
54.09
-1.82 (-3.26%)
At close: Sep 12, 2025, 4:00 PM EDT
54.45
+0.36 (0.67%)
After-hours: Sep 12, 2025, 7:57 PM EDT
BioMarin Pharmaceutical Employees
BioMarin Pharmaceutical had 3,040 employees as of December 31, 2024. The number of employees decreased by 361 or -10.61% compared to the previous year.
Employees
3,040
Change (1Y)
-361
Growth (1Y)
-10.61%
Revenue / Employee
$1,007,766
Profits / Employee
$216,198
Market Cap
10.39B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3,040 | -361 | -10.61% |
Dec 31, 2023 | 3,401 | 319 | 10.35% |
Dec 31, 2022 | 3,082 | 37 | 1.22% |
Dec 31, 2021 | 3,045 | -14 | -0.46% |
Dec 31, 2020 | 3,059 | 58 | 1.93% |
Dec 31, 2019 | 3,001 | 152 | 5.34% |
Dec 31, 2018 | 2,849 | 268 | 10.38% |
Dec 31, 2017 | 2,581 | 288 | 12.56% |
Dec 31, 2016 | 2,293 | 135 | 6.26% |
Dec 31, 2015 | 2,158 | 477 | 28.38% |
Dec 31, 2014 | 1,681 | 340 | 25.35% |
Dec 31, 2013 | 1,341 | 252 | 23.14% |
Dec 31, 2012 | 1,089 | 87 | 8.68% |
Dec 31, 2011 | 1,002 | 131 | 15.04% |
Dec 31, 2010 | 871 | 151 | 20.97% |
Dec 31, 2009 | 720 | 71 | 10.94% |
Dec 31, 2008 | 649 | 124 | 23.62% |
Dec 31, 2007 | 525 | 115 | 28.05% |
Dec 31, 2006 | 410 | 96 | 30.57% |
Dec 31, 2005 | 314 | -45 | -12.53% |
Dec 31, 2004 | 359 | 87 | 31.99% |
Dec 31, 2003 | 272 | 53 | 24.20% |
Dec 31, 2002 | 219 | 3 | 1.39% |
Dec 31, 2001 | 216 | 42 | 24.14% |
Dec 31, 2000 | 174 | 25 | 16.78% |
Dec 31, 1999 | 149 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BMRN News
- 4 days ago - BioMarin Pharmaceutical Inc. (BMRN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 days ago - PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment - Benzinga
- 5 days ago - BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting - PRNewsWire
- 7 days ago - BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism - PRNewsWire
- 9 days ago - BioMarin Pharmaceutical Inc. (BMRN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 10 days ago - BioMarin Pharmaceutical Inc. (BMRN) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 17 days ago - BioMarin to Participate in Upcoming Investor Conferences - PRNewsWire
- 5 weeks ago - BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401 - Seeking Alpha